Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients

Ten Years of Infliximab for Crohn’s Disease

(2013) Emma J. Eshuis et al.   INFLAMMATORY BOWEL DISEASES

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

(2012) C. Reenaers et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

(2012) Filip Baert et al.   Journal of Crohns & Colitis

Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease

(2012) S. Schreiber et al.   Journal of Crohns & Colitis

Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn’s disease

(2011) M. A. Kamm et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

(2011) E. Bultman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

(2011) L. S. Kiss et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

(2011) Matthias Jürgens et al.   Clinical Gastroenterology and Hepatology

Crohn's disease patients treated with adalimumab benefit from co-treatment with immunomodulators: Table 1

(2011) Mirthe E van der Valk et al.   GUT

Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial

(2011) Gert Van Assche et al.   GUT

Predictors of adalimumab dose escalation in patients with crohnʼs disease at a tertiary referral center

(2011) Russell D. Cohen et al.   INFLAMMATORY BOWEL DISEASES

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CARE

(2011) Robert Löfberg et al.   INFLAMMATORY BOWEL DISEASES

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy

(2010) S. Lichtiger et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn’s Disease

(2010) Cristina Nichita et al.   DIGESTION

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004-2008)

(2008) G. T. HO et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience

(2008) A. OUSSALAH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection

(2008) Miguel Regueiro et al.   GASTROENTEROLOGY